Plasma membrane lipid bilayer is druggable: Selective delivery of gemcitabine-squalene nano-medicine to cancer cells.
Fiche publication
Date publication
décembre 2022
Journal
Biochimica et biophysica acta. Molecular basis of disease
Auteurs
Membres identifiés du Cancéropôle Est :
Pr LIRUSSI Frédéric
Tous les auteurs :
Lirussi F, Pyrshev K, Yesylevskyy S, Rivel T, Lopez T, Coppens E, Mura S, Couvreur P, Ramseyer C
Lien Pubmed
Résumé
Up to now the lipid bilayers were rarely considered as targets in cancer therapy despite pronounced differences in lipid composition between plasma membranes of benign and malignant cells. In this study we demonstrate that the lipid bilayer of the plasma membrane is druggable and suitable for facilitating selective delivery of amphiphilic gemcitabine-squalene nanomedicines to cancer cells. Data from radioactive assays, fluorescent membrane probes and molecular dynamics simulations provide evidence of selective accumulation of gemcitabine-squalene in the plasma membranes with disrupted lipid asymmetry and its subsequent preferential uptake by malignant cells. This causes pronounced cytotoxicity on cancer cells in comparison to their benign counterparts originating from the same tissue.
Mots clés
Cancer targeting, Gemcitabine-squalene, Lipid composition, Nanomedicine, Plasma membrane, Selective delivery
Référence
Biochim Biophys Acta Mol Basis Dis. 2022 12 7;1869(2):166614